15 studies found for:    Open Studies | "Pneumococcal Infections"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Pneumococcal Infections"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)
Conditions: Streptococcus Pneumoniae Infection;   Pneumococcal Infections
Interventions: Biological: V114;   Biological: Prevnar 13
2 Recruiting Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae
Conditions: Pneumococcal Infections;   Pneumonia, Pneumococcal
Interventions: Biological: GEN-004 with Aluminum Hydroxide Adjuvant;   Biological: Placebo
3 Recruiting A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Condition: Pneumococcal Infection
Intervention: Biological: Prevnar 13 (PVC13)
4 Recruiting Aerosolized and Intravenous Colistin in Healthy Adults
Conditions: Pathogen Resistance;   Pneumococcal Infection;   Pneumonia
Interventions: Drug: Colistimethate (Colistin)Sodium-Intravenous;   Drug: Colistimethate (Colistin)Sodium-Aerosolized
5 Not yet recruiting Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses
Conditions: HIV;   Pneumococcal Infections;   Pneumococcal Vaccines
Interventions: Biological: PCV-13;   Biological: PPSV-23
6 Recruiting Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine (Synflorix™) When Administered to Children Who Are at an Increased Risk of Pneumococcal Infection
Condition: Infections, Streptococcal
Intervention: Biological: Synflorix™
7 Recruiting Systems Biology of 23-valent Pneumococcal Polysaccharide Vaccine (PNEUMOVAX®23) and 13-valent Pneumococcal Conjugate Vaccine (PREVNAR 13®)
Condition: Pneumococcal Infection
Interventions: Biological: PNEUMOVAX and PREVNAR;   Biological: Pneumovax or Prevnar
8 Recruiting A Study to Evaluate the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)
Condition: Pneumococcal Infections
Interventions: Biological: Prevnar 13™;   Biological: Pneumovax™ 23;   Biological: Placebo
9 Unknown  PneuMum: Pneumococcal Vaccination of Australian Indigenous Mothers to See if it Protects Their Babies From Ear Disease
Conditions: Middle Ear Effusion;   Tympanic Membrane Perforation;   Acute Otitis Media;   Pneumococcal Infections
Intervention: Biological: 23 valent pneumococcal polysaccharide vaccine
10 Not yet recruiting An Incitative Multifaceted PROcedure for Pneumococcal Vaccination at the Emergency Department
Condition: Pneumococcal Infections
Intervention:
11 Recruiting Protection Against Pneumococcal Infection in Children With T1DM
Condition: Type 1 Diabetes Mellitus
Intervention: Biological: 13-valent pneumococcal conjugate vaccine (PCV13)
12 Not yet recruiting Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers
Condition: Pneumonia, Pneumococcal
Interventions: Biological: PATH-wSP;   Biological: pneumococcal polysaccharide conjugate vaccine (adsorbed);   Biological: Diptheria Pertussis Tetanus Hep B Haemophilus b Conjugate;   Other: Saline
13 Recruiting Study on the Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old.
Conditions: Seizures;   Pneumococcal Meningitis
Interventions: Drug: Phenytoin;   Drug: placebo
14 Not yet recruiting Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older
Condition: Influenza
Interventions: Biological: Influsplit™ Tetra (Fluarix™ Tetra);   Biological: Pneumovax 23/Pneumovax;   Biological: Placebo
15 Recruiting Multicenter Pilot Study Evaluating the Immunogenicity of an Innovative Pneumococcal Vaccination Strategy in Splenectomized Adults
Condition: Splenectomized Patients
Intervention: Biological: Prime-boost pneumococcal immunization

Indicates status has not been verified in more than two years